Immunoglobulins Market (Applications - Neurology, Immunology, Hematology; Route of Administration - Intravenous, Subcutaneous, Intramuscular; End user - Hospital, Clinic, Homecare) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2030

Global Immunoglobulins Market - Snapshot

The global immunoglobulins market is expected to reach a market value of about US$ 20,757 Mn by the end of 2026, expanding at a high single digit CAGR during the forecast period. Rise in prevalence of diseases related to neurology, immunology, hematology, and other deficiencies, rising geriatric population across the globe, leading to diseases, adoption, and awareness of effective immunoglobulins products, improving healthcare infrastructure, and rich product pipeline are expected to boost the global immunoglobulins market during the forecast period. Surge in investments by key players through collaborations, mergers, and acquisition are expected to propel the global immunoglobulins market during the forecast period. However, the high cost of treatments and severe side-effects associated with infusions are expected to hamper the immunoglobulins market. Niche rare disease segment with limited product availability is likely to fuel the market. 

The global immunoglobulins market has been segmented based on applications, route of administration, and end-user. In terms of applications, the global market has been classified into neurology, immunology, hematology, and others. The neurology segment dominates the global immunoglobulins market, in terms of value, owing to its indication prevalence. This immunology segment is expected to expand at a significant CAGR owing to higher prevalence of idiopathic thrombocytopenic purpura (ITP), primary immunodeficiency, and other indications. Based on route of administration, the global immunoglobulins market has been divided into intravenous, subcutaneous, and intramuscular. The intravenous segment held a major share of the market in 2017. It is expected to maintain its leading position, in terms of market share, during the forecast period owing to its rapid onset of action. However, benefits of subcutaneous over intravenous are presently slowly adaptable in the market and hence, the subcutaneous segment is projected to expand at a notable CAGR during the forecast period. 

In terms of end-user, the global immunoglobulins market has been segregated into hospital, clinic, and homecare. The hospital segment held a major share of the market in 2017, followed by clinic and homecare segments, owing to the acceptance of advanced treatment requiring hospitalization. The homecare segment is projected to expand at a considerable CAGR during the forecast period owing to easy administration of infusions at home, supporting personal care, as well as it saves the cost of treatment. In developing countries, the medical care isn’t funded completely by the government; hence, the rising adoption of homecare is advantageous to patients. Preference of subcutaneous products is also driving the homecare segment 

In terms of geography, the global immunoglobulins market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global immunoglobulins market owing to major acceptance of intravenous infusions, increasing plasma yield, healthcare investments by the government, and presence of major players in the region. According to the Immune Deficiency Foundation (IDF), there are more than 5 million undiagnosed cases in the U.S., which in turn is driving innovative therapeutic treatments and huge investments. Rising incidence of neurological, autoimmune disorders is boosting the demand for effective treatment, which in turn is a major factor driving the market in North America. The market in Asia Pacific is projected to expand at a significantly high CAGR during the forecast period, owing to improving health care infrastructure, rising investments in research and development, increasing disposable income, awareness about IVIG infusions in countries, such as China and India, and increasing acceptance of SCIG infusions in the region. IVIG accounts for a prominent share of the plasma market in China. Furthermore, the prevalence of CIDP, ITP diseases is anticipated to further boost the market in Asia Pacific in the near future. 

Major players operating in the global immunoglobulins market include Shire, CSL Behring, Kedrion Biopharma Inc, Grifols, S.A., Octapharma, China Biologic Products Holdings Inc, Biotest AG, Sanquin, and LFB SA. Key players are focusing on geographic expansion through acquisitions and collaborations to enhance their footprint in the global immunoglobulins market. Furthermore, companies are investing in pipeline products for building strong product portfolio.

IVIg Usage in Treating Severe COVID-19 Cases will bring Good Growth Opportunities for the Immunoglobulins Market

The immunoglobulins market is extrapolated to gain intensive growth opportunities owing to the increasing cases of immunodeficiency. The changing lifestyle habits and hectic work schedules have led to problems related to immunodeficiency. Thus, this aspect will bring good growth opportunities for the immunoglobulins market during the forecast period of 2018-2026.

Immunoglobulins are glycoproteins created in response to an immunogen by plasma cells and act as antibodies. They generally bind to antigenic determinants and eliminate the threat of infections. Hence, all these aspects bring exponential growth for the immunoglobulins market.

The booming geriatric population and a rise in the number of hemophilic patients will serve as a vital growth generator for the immunoglobulins market. The popularity of immunoglobulin therapy as the preferred treatment for immunodeficiency and other rare neurological diseases may invite exponential growth for the immunoglobulins market. The escalating focus on immune disorder diagnosis will serve as a prominent growth factor. Quick regulatory approvals are also helping in boosting the growth prospects of the immunoglobulins market.

Research and development activities are playing a crucial role in the growth of the immunoglobulins market. The players in the immunoglobulins market focus on these activities for discovering unique insights. The insights assist in boosting the revenues of the players in the immunoglobulins market, ultimately adding extra stars of growth.

The COVID-19 outbreak is one of the worst pandemics the world has ever faced. The rapid transmission rate and the high fatality rate have left many scientists and researchers searching for a good treatment option. Many options have been discovered by researchers and scientists. The utilization of immunoglobulins is one of them. The utilization of Intravenous immunoglobulin (IVIg) for treating serious COVID-19 patients is being considered by many scientists and researchers. A recent study also showcased the efficacy of IVIg in treating COVID-19 patients. Thus, this aspect can bring great growth opportunities for the immunoglobulins market.

The global immunoglobulins market has been segmented as below:

by Applications

• Neurology
• Immunology
• Hematology
• Others

by Route Of Administration

• Intravenous
• Subcutaneous
• Intramuscular

by End-user

• Hospital
• Clinic
• Homecare

by Region

• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• France
• Italy
• Spain
• Rest of Europe
• Asia Pacific
• India
• China
• Japan
• Australia & New Zealand
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Middle East & Africa
• South Africa
• GCC Countries
• Rest of Middle East & Africa

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Immunoglobulins Market

4. Market Overview
     4.1. Introduction
            4.1.1. Market Definition
            4.1.2. Industry Evolution / Developments
     4.2. Overview
     4.3. Market Dynamics
            4.3.1. Drivers
            4.3.2. Restraints
            4.3.3. Opportunities
     4.4. Global Immunoglobulins Market Analysis and Forecast, 2016–2026
            4.4.1. Global Immunoglobulins Market Value (US$ Mn) Projections
     4.5. Porter’s Five Force Analysis

5. Market Outlook
     5.1. Disease Prevalence & Incidence Rate Globally with Key Countries
     5.2. Regulatory Scenario by Region/globally
     5.3. Pipeline Analysis

6. Global Immunoglobulins Market Analysis and Forecast, by Applications 
     6.1. Introduction & Definition
     6.2. Key Findings / Developments
     6.3. Global Immunoglobulins Market Value Forecast, by Applications, 2016–2026
            6.3.1. Neurology
            6.3.2. Immunology
            6.3.3. Hematology
            6.3.4. Others
     6.4. Global Immunoglobulins Market Attractiveness by Applications 

7. Global Immunoglobulins Market Analysis and Forecast, by Route of Administration 
     7.1. Introduction & Definition
     7.2. Key Findings / Developments
     7.3. Global Immunoglobulins Market Value Forecast, by Route of Administration, 2016–2026
            7.3.1. Intravenous
            7.3.2. Subcutaneous
            7.3.3. Intramuscular     
     7.4. Global Immunoglobulins Market Attractiveness by Route of Administration 

8. Global Immunoglobulins Market Analysis and Forecast, by End-user 
     8.1. Introduction & Definition
     8.2. Key Findings / Developments
     8.3. Global Immunoglobulins Market Value Forecast, by End-user, 2016–2026
            8.3.1. Hospital
            8.3.2. Clinic
            8.3.3. Homecare
     8.4. Global Immunoglobulins Market Attractiveness by End-user 

9. Global Immunoglobulins Market Analysis and Forecast, by Region
     9.1. Key Findings
     9.2. Global Immunoglobulins Market Value Forecast, by Region
            9.2.1. North America 
            9.2.2. Europe 
            9.2.3. Asia Pacific 
            9.2.4. Latin America 
            9.2.5. Middle East & Africa      
     9.3. Global Immunoglobulins Market Attractiveness, by Country/Region

10. North America Immunoglobulins Market Analysis and Forecast
     10.1. Introduction
            10.1.1. Key Findings
     10.2. North America Immunoglobulins Market Value Forecast, by Applications, 2016–2026
            10.2.1. Neurology
            10.2.2. Immunology
            10.2.3. Hematology
            10.2.4. Others
     10.3. North America Immunoglobulins Market Value Forecast, by Route of Administration, 2016–2026
            10.3.1. Intravenous
            10.3.2. Subcutaneous
            10.3.3. Intramuscular
     10.4. North America Immunoglobulins Market Value Forecast, by End-user, 2016–2026
            10.4.1. Hospital
            10.4.2. Clinic
            10.4.3. Homecare
     10.5 North America Immunoglobulins Market Value Forecast, by Country, 2016–2026
            10.5.1. US
            10.5.2. Canada 
     10.6. North America Immunoglobulins Market Attractiveness Analysis 
            10.6.1. By Applications 
            10.6.2. By Route of Administration 
            10.6.3. By End-user 
            10.6.4. By Country

11. Europe Immunoglobulins Market Analysis and Forecast
     11.1. Introduction
            11.1.1. Key Findings
     11.2. Europe Immunoglobulins Market Value Forecast by Applications, 2016–2026
            11.2.1. Neurology
            11.2.2. Immunology
            11.2.3. Hematology
            11.2.4. Others
     11.3. Europe Immunoglobulins Market Value Forecast, by Route of Administration, 2016–2026
            11.3.1. Intravenous
            11.3.2. Subcutaneous
            11.3.3. Intramuscular
     11.4. Europe Immunoglobulins Market Value Forecast, by End-user, 2016–2026
            11.4.1. Hospital
            11.4.2. Clinic
            11.4.3. Homecare
     11.5. Europe Immunoglobulins Market Value Forecast, by Country/Sub-region, 2016–2026
            11.5.1. Germany
            11.5.2. France
            11.5.3. U.K.
            11.5.4. Italy
            11.5.5. Spain
            11.5.6. Rest of Europe
     11.6. Europe Immunoglobulins Market Attractiveness Analysis 
            11.6.1. By Applications 
            11.6.2. By Route of Administration 
            11.6.3. By End-user 
            11.6.4. By Country/Sub-region

12. Asia Pacific Immunoglobulins Market Analysis and Forecast
     12.1. Introduction
            12.1.1. Key Findings
     12.2. Asia Pacific Immunoglobulins Market Value Forecast, by Applications, 2016–2026
            12.2.1. Neurology
            12.2.2. Immunology
            12.2.3. Hematology
            12.2.4. Others
     12.3. Asia Pacific Immunoglobulins Market Value Forecast, by Route of Administration, 2016–2026
            12.3.1. Intravenous
            12.3.2. Subcutaneous
            12.3.3. Intramuscular
     12.4. Asia Pacific Immunoglobulins Market Value Forecast, by End-user, 2016–2026
            12.4.1. Hospital
            12.4.2. Clinic
            12.4.3. Homecare
     12.5. Asia Pacific Immunoglobulins Market Value Forecast, by Country/Sub-region, 2016–2026
            12.5.1. Japan
            12.5.2. China
            12.5.3. India
            12.5.4. Australia & New Zealand
            12.5.5. Rest of Asia Pacific
     12.6. Asia Pacific Immunoglobulins Market Attractiveness Analysis 
            12.6.1. By Applications 
            12.6.2. By Route of Administration 
            12.6.3. By End-user 
            12.6.4. By Country/Sub-region

13. Latin America Immunoglobulins Market Analysis and Forecast
     13.1. Introduction
            13.1.1. Key Findings
     13.2. Latin America Immunoglobulins Market Value Forecast, by Applications, 2016–2026
            13.2.1. Neurology
            13.2.2. Immunology
            13.2.3. Hematology
            13.2.4. Others
     13.3. Latin America Immunoglobulins Market Value Forecast, by Route of Administration, 2016–2026
            13.3.1. Intravenous
            13.3.2. Subcutaneous
            13.3.3. Intramuscular
     13.4. Latin America Immunoglobulins Market Value Forecast, by End-user, 2016–2026
            13.4.1. Hospital
            13.4.2. Clinic
            13.4.3. Homecare
     13.5. Latin America Immunoglobulins Market Value Forecast, by Country/Sub-region, 2016–2026
            13.5.1. Brazil
            13.5.2. Mexico
            13.5.3. Rest of Latin America
     13.6. Latin America Immunoglobulins Market Attractiveness Analysis 
            13.6.1. By Applications 
            13.6.2. By Route of Administration 
            13.6.3. By End-user 
            13.6.4. By Country/Sub-region

14. Middle East & Africa Immunoglobulins Market Analysis and Forecast
     14.1. Introduction
            14.1.1. Key Findings
     14.2. Latin America Immunoglobulins Market Value Forecast, by Applications, 2016–2026
            14.2.1. Neurology
            14.2.2. Immunology
            14.2.3. Hematology
            14.2.4. Others
     14.3. Latin America Immunoglobulins Market Value Forecast, by Route of Administration, 2016–2026
            14.3.1. Intravenous
            14.3.2. Subcutaneous
            14.3.3. Intramuscular
     14.4. Latin America Immunoglobulins Market Value Forecast, by End-user, 2016–2026
            14.4.1. Hospital
            14.4.2. Clinic
            14.4.3. Homecare
     14.5. Latin America Immunoglobulins Market Value Forecast, by Country/Sub-region, 2016–2026
            14.5.1. GCC Countries
            14.5.2. South Africa
            14.5.3. Rest of Middle East & Africa
     14.6. Latin America Immunoglobulins Market Attractiveness Analysis 
            14.6.1. By Applications 
            14.6.2. By Route of Administration 
            14.6.3. By End-user 
            14.6.4. By Country/Sub-region
            
15. Competition Landscape
     15.1. Market Player – Competition Matrix (by Tier and Size of companies)
     15.2. Market Share Analysis by Company (2016)
     15.3. Company Profiles
            15.3.1. Shire
            15.3.2. CSL Behring 
            15.3.3. Kedrion Biopharma Inc 
            15.3.4. Grifols, S.A.
            15.3.5. Octapharma
            15.3.6. China Biologic Products Holdings, Inc
            15.3.7. Biotest AG
            15.3.8. Sanquin
            15.3.9. LFB SA